Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010–2014)
10.24304/kjcp.2019.29.2.79
- Author:
Jung Eun HA
1
;
Eun Jin JANG
;
Seul Gi IM
;
Hyun Soon SOHN
Author Information
1. College of Pharmacy, CHA University, Gyenggi-do 13488, Republic Republic of Korea. sohn64@cha.ac.kr
- Publication Type:Original Article
- Keywords:
Inflammatory bowel disease;
ulcerative colitis;
Crohn's disease;
drug therapy;
real world data
- MeSH:
Colitis, Ulcerative;
Crohn Disease;
Drug Therapy;
Health Expenditures;
Humans;
Inflammatory Bowel Diseases;
Mesalamine;
National Health Programs;
Necrosis;
Prescriptions;
Prevalence
- From:Korean Journal of Clinical Pharmacy
2019;29(2):79-88
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUNDS: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD) increased prevalence and economic burden. OBJECTIVES: This study aimed to investigate drug use pattern in IBD patients in a real world. METHODS: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-α agent(anti TNF-α). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. RESULTS: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40–50 (41.2%) and 20–30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-α use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. CONCLUSIONS: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.
